Weight management is now one of the major global health challenges. In recent years, GLP-1 receptor agonist drugs – such as semaglutide and tirzepatide – have radically changed the approach to the treatment of obesity and type 2 diabetes. In the United States, their use has increased rapidly, rising from 10% in 2024 to about 18% in 2025 among people with clinical indications. This trend reflects growing interest in therapies capable of influencing not only blood glucose levels but also the mechanisms that regulate appetite.

What Are Incretins?

Incretins are gut-derived hormones released after the intake of nutrients, particularly carbohydrates and lipids. The most relevant are GLP-1 and GIP. Both regulate the metabolic response to meals by stimulating insulin secretion only when blood glucose is elevated, reducing hepatic glucose production, and slowing gastric emptying. The combined effect is a longer-lasting feeling of fullness and more stable control of glucose levels.

GLP-1 also plays a key role in the central nervous system, where it contributes to modulating the neural circuits that regulate hunger. However, its physiological half-life is extremely short – less than two minutes – due to rapid degradation by the DPP-IV enzyme. This led to the development of GLP-1 receptor agonists, molecules resistant to degradation and capable of maintaining a prolonged therapeutic effect.

GLP-1 and Weight Loss

The use of GLP-1 agonists has shown a dual benefit. On one side, they significantly improve glycemic homeostasis; on the other, they reduce appetite and caloric intake, which translates into a decrease in fat mass. This combined effect underlies their impact on weight management, even in individuals who may not respond to other therapeutic approaches.

Among the first representatives of this class was exenatide, followed by more recent molecules such as liraglutide, semaglutide, and tirzepatide, each characterized by increasingly longer half-lives and superior clinical efficacy.

Changes in Eating Behaviors

The widespread adoption of GLP-1–based medications is also driving changes in dietary patterns. Users commonly report a spontaneous reduction in appetite and a greater sensitivity to high-fat foods. This naturally leads to a preference for foods higher in protein, fiber, and micronutrients, and to the search for meals with lower caloric density. For the nutrition industry, this evolution represents an opportunity to develop products that meet these needs: nutrient-dense yet light, and able to complement – without replacing – pharmacological therapy.

The Role of Supplements in Supporting the GLP-1 System

It is important to clarify that supplements do not replicate the pharmacological action of GLP-1 agonists. However, they can indirectly support certain physiological processes related to satiety, glycemic response, and energy metabolism.

Soluble fibers and proteins, for example, can naturally prolong satiety and modulate the postprandial glycemic response, supporting a more balanced release of incretins. Certain bioactive ingredients – such as blends formulated to enhance insulin sensitivity, including Metaglp+ – work primarily by improving the quality of the cellular response to glucose, contributing to a more favorable metabolic environment.

The microbiome also plays an essential role: a well-balanced gut produces higher levels of incretins such as GLP-1 and PYY. Specific prebiotics and probiotics can therefore contribute, indirectly but meaningfully, to appetite regulation and weight management through the modulation of the enteroendocrine system.

A Potential Supportive Option: MetaGLP+

Among the ingredients designed to support metabolic responses, an interesting role is played by formulations developed to improve insulin sensitivity and promote more efficient enteroendocrine signaling. MetaGLP+ falls into this category: it combines selected bioactive compounds with the goal of optimizing glucose management, supporting microbiota function, and creating a physiological environment conducive to the natural production of incretins.

It is not a substitute for GLP-1 agonist drugs nor a direct activator of the receptor. Its value lies instead in supporting the processes that precede hormonal signaling: glycemic stability, mitochondrial efficiency, cellular signaling quality, and gut health. In a context where consumers are seeking integrative solutions compatible with the changes induced by GLP-1 therapies, products such as MetaGLP+ represent a potentially useful complement within a broader strategy for weight and metabolic management.

Learn more about MetaGLP+ on this page.